Spero Therapeutics Inc.

NASDAQ: SPRO · Real-Time Price · USD
2.86
0.36 (14.40%)
At close: Jun 02, 2025, 11:13 AM

Spero Therapeutics Revenue Breakdown

Period Ending Dec 31, 2024
Collaboration Revenue Related Party Revenue 27.02M
Collaboration Revenue Related Party Revenue Growth n/a
Collaboration Revenue Revenue 371K
Collaboration Revenue Revenue Growth n/a
Grant Revenue Revenue 20.58M
Grant Revenue Revenue Growth n/a

Operating Expense Breakdown

Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016
Selling, General, and Administrative Revenue 6.82M 7.06M 5.2M 5.53M 5.92M 6.43M 5.71M 6.1M 7.32M 6.5M 6.63M 8.05M 15.3M 13.02M 11.15M 9.23M 8.3M 7.5M 5.31M 4.55M 4.09M 3.79M 4.13M 3.78M 3.89M 3.65M 3.13M 3.06M 3.04M 2.49M 3.65M 2.96M 1.74M 2.22M 1.91M
Selling, General, and Administrative Revenue Growth -3.29% +35.74% -6.05% -6.49% -8.02% +12.70% -6.36% -16.69% +12.66% -2.07% -17.63% -47.40% +17.54% +16.76% +20.84% +11.21% +10.68% +41.23% +16.76% +11.28% +7.95% -8.42% +9.28% -2.73% +6.55% +16.43% +2.42% +0.53% +22.25% -31.84% +23.54% +69.94% -21.55% +16.19% n/a
Research and Development Revenue 13.61M 28.84M 26.86M 23.73M 17.33M 16.52M 16.39M 9.51M 8.98M 15.09M 7.36M 8.17M 16.97M 17.23M 14.44M 14.46M 18.4M 13.21M 17.71M 15.66M 20.44M 25.73M 18.5M 12.03M 9.53M 9.13M 8.46M 7.37M 8.93M 12.5M 6.91M 7.46M 6M 6.93M 6M
Research and Development Revenue Growth -52.82% +7.34% +13.23% +36.89% +4.92% +0.77% +72.38% +5.91% -40.49% +105.01% -9.95% -51.84% -1.47% +19.32% -0.17% -21.42% +39.37% -25.42% +13.09% -23.39% -20.57% +39.11% +53.79% +26.24% +4.37% +7.90% +14.71% -17.38% -28.62% +80.94% -7.34% +24.30% -13.40% +15.35% n/a